Chorea Market Trends, Growing Demand, Synopsis, Opportunities and Analysis 2022 to 2030
Ngày đăng: 20-09-2023 |
Ngày cập nhật: 20-09-2023
Market Highlights
Chorea is a nonrhythmic, rapid, nonsuppressible involuntary movement. Chorea is often worsened by anxiety, stress and subsides during sleep. It is also found that most patients attempt to disguise chorea by a purposeful activity. Sydenham’s chorea is the most common form of chorea in childhood, whereas Huntington’s disease, and drug induced chorea found mostly in adult onset cases.
A number of factor such as growing public awareness, and technological advancements, rising prevalence of neurological disorders, increasing awareness, improving regulatory framework, increasing government assistance, increasing adoption rate, and rising funding and reimbursement policies are propelling the growth of the global chorea market.
However, challenges in research and development, side-effects of treatment, cost of treatment, the presence of misbranded and spurious drugs and poor healthcare system in low and middle-income countries may hamper the growth of the market.
The Chorea Market is expected to reach USD 2,458.5 Million by 2030 at 12.4% CAGR during the forecast period 2022-2030.
The Chorea market refers to the healthcare sector's focus on the diagnosis, treatment, and management of Chorea, a neurological disorder characterized by involuntary, rapid, and irregular movements of the limbs, face, and torso. This market encompasses a range of pharmaceuticals, therapeutic interventions, and diagnostic tools aimed at addressing Chorea's underlying causes and alleviating its symptoms. It includes medications, such as antipsychotics and dopamine-depleting agents, as well as emerging therapies like gene editing and deep brain stimulation. Additionally, the market involves research into understanding the genetic basis of Chorea, with potential breakthroughs in precision medicine. As the prevalence of neurological disorders rises, the Chorea market continues to evolve, driven by advancements in medical science and technology.
Regional Analysis
The Americas dominate the chorea market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the chorea market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing chorea market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Segmentation
The Global Chorea Market is segmented on the basis of type, treatment, and distribution channels.
On the basis of the type, the market is classified as Huntington’s disease, Rheumatic (Sydenham’s chorea), and Drug-induced chorea.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into neuroleptics, dopamine-depleting agents, GABAergic drugs, coenzyme Q10, intravenous immunoglobulin, and plasmapheresis. The sub segments neuroleptic includes, typical neuroleptics, and atypical neuroleptics. The surgical care is further segmented into deep brain stimulation, and cell transplantation.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Key Players
Some of key the players in the global chorea market are Teva Pharmaceutical Industries Ltd., Valeant, Medtronic, Alnylam Pharmaceuticals, Inc., Cyberonics, Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Boston Scientific Corporation, GlaxoSmithKline plc, Lundbeck, Prana Biotechnology Limited, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, SOM Biotech, Raptor Pharmaceutical, Omeros, Ipsen, Pfizer, Palobiofarma, Aleva Neurotherapeutics SA, and other
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Chorea is a nonrhythmic, rapid, nonsuppressible involuntary movement. Chorea is often worsened by anxiety, stress and subsides during sleep. It is also found that most patients attempt to disguise chorea by a purposeful activity. Sydenham’s chorea is the most common form of chorea in childhood, whereas Huntington’s disease, and drug induced chorea found mostly in adult onset cases.
A number of factor such as growing public awareness, and technological advancements, rising prevalence of neurological disorders, increasing awareness, improving regulatory framework, increasing government assistance, increasing adoption rate, and rising funding and reimbursement policies are propelling the growth of the global chorea market.
However, challenges in research and development, side-effects of treatment, cost of treatment, the presence of misbranded and spurious drugs and poor healthcare system in low and middle-income countries may hamper the growth of the market.
The Chorea Market is expected to reach USD 2,458.5 Million by 2030 at 12.4% CAGR during the forecast period 2022-2030.
The Chorea market refers to the healthcare sector's focus on the diagnosis, treatment, and management of Chorea, a neurological disorder characterized by involuntary, rapid, and irregular movements of the limbs, face, and torso. This market encompasses a range of pharmaceuticals, therapeutic interventions, and diagnostic tools aimed at addressing Chorea's underlying causes and alleviating its symptoms. It includes medications, such as antipsychotics and dopamine-depleting agents, as well as emerging therapies like gene editing and deep brain stimulation. Additionally, the market involves research into understanding the genetic basis of Chorea, with potential breakthroughs in precision medicine. As the prevalence of neurological disorders rises, the Chorea market continues to evolve, driven by advancements in medical science and technology.
Regional Analysis
The Americas dominate the chorea market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the chorea market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing chorea market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Segmentation
The Global Chorea Market is segmented on the basis of type, treatment, and distribution channels.
On the basis of the type, the market is classified as Huntington’s disease, Rheumatic (Sydenham’s chorea), and Drug-induced chorea.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into neuroleptics, dopamine-depleting agents, GABAergic drugs, coenzyme Q10, intravenous immunoglobulin, and plasmapheresis. The sub segments neuroleptic includes, typical neuroleptics, and atypical neuroleptics. The surgical care is further segmented into deep brain stimulation, and cell transplantation.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Key Players
Some of key the players in the global chorea market are Teva Pharmaceutical Industries Ltd., Valeant, Medtronic, Alnylam Pharmaceuticals, Inc., Cyberonics, Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Boston Scientific Corporation, GlaxoSmithKline plc, Lundbeck, Prana Biotechnology Limited, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, SOM Biotech, Raptor Pharmaceutical, Omeros, Ipsen, Pfizer, Palobiofarma, Aleva Neurotherapeutics SA, and other
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Thông tin liên hệ
: khusijones97
:
:
:
:
